These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 1615580

  • 1. Differential sensitivity of hormone-responsive and unresponsive human prostate cancer cells (LNCaP) to tumor necrosis factor.
    Zhao X, van Steenbrugge GJ, Schröder FH.
    Urol Res; 1992; 20(3):193-7. PubMed ID: 1615580
    [Abstract] [Full Text] [Related]

  • 2. The human prostatic carcinoma cell line LNCaP and its derivatives. An overview.
    van Steenbrugge GJ, Groen M, van Dongen JW, Bolt J, van der Korput H, Trapman J, Hasenson M, Horoszewicz J.
    Urol Res; 1989; 17(2):71-7. PubMed ID: 2660395
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines.
    Sokoloff MH, Tso CL, Kaboo R, Taneja S, Pang S, deKernion JB, Belldegrun AS.
    Cancer; 1996 May 01; 77(9):1862-72. PubMed ID: 8646686
    [Abstract] [Full Text] [Related]

  • 7. Androgens inhibit the proliferation of a variant of the human prostate cancer cell line LNCaP.
    Joly-Pharaboz MO, Soave MC, Nicolas B, Mebarki F, Renaud M, Foury O, Morel Y, Andre JG.
    J Steroid Biochem Mol Biol; 1995 Oct 01; 55(1):67-76. PubMed ID: 7577722
    [Abstract] [Full Text] [Related]

  • 8. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
    Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A, Bartsch G, Utermann G, Schneider MR, Parczyk K, Klocker H.
    Br J Cancer; 1999 Sep 01; 81(2):242-51. PubMed ID: 10496349
    [Abstract] [Full Text] [Related]

  • 9. Possible role of adaptive mutation in resistance to antiandrogen in prostate cancer cells.
    Hara T, Kouno J, Nakamura K, Kusaka M, Yamaoka M.
    Prostate; 2005 Nov 01; 65(3):268-75. PubMed ID: 16015592
    [Abstract] [Full Text] [Related]

  • 10. LNCaP prostatic adenocarcinoma cells derived from low and high passage numbers display divergent responses not only to androgens but also to retinoids.
    Esquenet M, Swinnen JV, Heyns W, Verhoeven G.
    J Steroid Biochem Mol Biol; 1997 Aug 01; 62(5-6):391-9. PubMed ID: 9449242
    [Abstract] [Full Text] [Related]

  • 11. 1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent.
    Zhao XY, Ly LH, Peehl DM, Feldman D.
    Endocrinology; 1997 Aug 01; 138(8):3290-8. PubMed ID: 9231780
    [Abstract] [Full Text] [Related]

  • 12. Vitamin E and other antioxidants inhibit human prostate cancer cells through apoptosis.
    Gunawardena K, Murray DK, Meikle AW.
    Prostate; 2000 Sep 01; 44(4):287-95. PubMed ID: 10951493
    [Abstract] [Full Text] [Related]

  • 13. Role of growth factors, steroid and peptide hormones in the regulation of human prostatic tumor growth.
    Motta M, Dondi D, Moretti RM, Montagnani Marelli M, Pimpinelli F, Maggi R, Limonta P.
    J Steroid Biochem Mol Biol; 1996 Jan 01; 56(1-6 Spec No):107-11. PubMed ID: 8603030
    [Abstract] [Full Text] [Related]

  • 14. Androgen and taxol cause cell type-specific alterations of centrosome and DNA organization in androgen-responsive LNCaP and androgen-independent DU145 prostate cancer cells.
    Schatten H, Ripple M, Balczon R, Weindruch R, Chakrabarti A, Taylor M, Hueser CN.
    J Cell Biochem; 2000 Jan 01; 76(3):463-77. PubMed ID: 10649443
    [Abstract] [Full Text] [Related]

  • 15. Effect of culture conditions on androgen sensitivity of the human prostatic cancer cell line LNCaP.
    Langeler EG, van Uffelen CJ, Blankenstein MA, van Steenbrugge GJ, Mulder E.
    Prostate; 1993 Jan 01; 23(3):213-23. PubMed ID: 7694266
    [Abstract] [Full Text] [Related]

  • 16. Antiproliferative activity of casodex (ICI 176.334) in hormone-dependent tumours.
    Maucher A, von Angerer E.
    J Cancer Res Clin Oncol; 1993 Jan 01; 119(11):669-74. PubMed ID: 8349724
    [Abstract] [Full Text] [Related]

  • 17. Enhancement of antiproliferative effects of interleukin-1beta and tumor necrosis factor-alpha on human prostate cancer LNCaP cells by coculture with normal fibroblasts through secreted interleukin-6.
    Kawada M, Ishizuka M, Takeuchi T.
    Jpn J Cancer Res; 1999 May 01; 90(5):546-54. PubMed ID: 10391095
    [Abstract] [Full Text] [Related]

  • 18. Estrogens affect endothelin-1 mRNA expression in LNCaP human prostate carcinoma cells.
    Grande M, Carlström K, Stege R, Pousette A, Faxén M.
    Eur Urol; 2002 May 01; 41(5):568-72; discussion 573-4. PubMed ID: 12074801
    [Abstract] [Full Text] [Related]

  • 19. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
    Hara T, Miyazaki J, Araki H, Yamaoka M, Kanzaki N, Kusaka M, Miyamoto M.
    Cancer Res; 2003 Jan 01; 63(1):149-53. PubMed ID: 12517791
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.